Dako announces a collaboration with OSI Pharmaceuticals, Inc. on Companion Diagnostics

30-Jan-2009 - Denmark

Dako has entered into a collaboration with OSI Pharmaceuticals, Inc. Under the terms of agreement, Dako and OSI Pharmaceuticals, Inc. will collaborate on developing a new cancer diagnostic test as a potential companion product for a cancer therapy.

The new cancer diagnostic test is intended to identify patients more likely to benefit from a specific treatment. The collaboration will draw on Dako's extensive experience within the development of cancer diagnostic tests and OSI Pharmaceuticals' thorough knowledge in developing and commercializing novel pharmaceutical products.

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper